Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis

Hiroaki Nagano, Hiroshi Wada, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Masahiro Tanemura, Yoshito Tomimaru, Keigo Osuga, Koji Umeshita, Yuichiro Doki, Masaki Mori

研究成果: Contribution to journalArticle

34 引用 (Scopus)

抜粋

Background/Aim: We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches. This report describes the results of longer follow-up and includes more than twice the number of patients relative to the previous report; it also evaluates the clinical predictor on the response to the combination therapy and long-term survival. Methods: The study subjects were 102 patients with advanced HCC and tumor thrombi in the major branches of the portal vein (Vp3 or 4). They were treated with at least 2 courses of IFN-α/5-FU. Results: No major treatment-related complications were noted. In the 102 patients, 40 (39.2%) showed objective response [11 (10.8%) showed complete response, 29 (28.4%) partial response], 8 (7.9%) showed no response and 54 (52.9%) showed progressive disease. Conclusion: IFN-α/5-FU combination therapy is a promising modality for advanced HCC with tumor thrombi in the major portal branches.

元の言語英語
ページ(範囲)63-69
ページ数7
ジャーナルOncology
80
発行部数1-2
DOI
出版物ステータス出版済み - 6 2011

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Eguchi, H., Tanemura, M., Tomimaru, Y., Osuga, K., Umeshita, K., Doki, Y., & Mori, M. (2011). Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology, 80(1-2), 63-69. https://doi.org/10.1159/000328281